CompoCT
Integrating CT-Based Body Composition and Laboratory Tests to predict Sarcopenia
Cancer immunotherapy has revolutionized treatment paradigms, yet the variability in patient response remains a critical challenge. Traditional biomarkers such as PD-L1 expression, tumor mutational burden, and MSI status offer only partial predictive power. Emerging research highlights the pivotal role of body composition—specifically the ratio of adipose to lean tissue—in modulating immune response and influencing immunotherapy outcomes. Recent clinical data underscore that obese and sarcopenic patients exhibit significantly different progression-free and overall survival rates compared to individuals with balanced body composition, suggesting the potential of these physiological markers as robust predictive tools.
Inventors
Prof. Salomon Stemmer
Prof. Gal Markel
Dr. Shlomit Tamir
Contact info
For further information please contact:
Sari Prutchi Sagiv PhD Director of Pharma and Diagnostics
Our research team has developed an innovative AI-driven platform that analyzes body composition data from standard CT scans to stratify patients by their expected response to immunotherapy.
This non-invasive, image-based approach leverages existing radiographic data to assess muscle mass and adipose tissue distribution, providing clinicians with a personalized prediction of treatment efficacy. The system integrates seamlessly into clinical workflows and supports real-time decision-making, enabling oncologists to optimize treatment plans and improve patient outcomes based on individual physiological profiles.
This technology introduces a paradigm shift in precision oncology by positioning body composition as a scalable, cost-effective biomarker for immunotherapy success. With the global immuno-oncology market projected to surpass $150 billion by 2030, the need for reliable predictive tools is urgent.
Our solution not only enhances patient stratification but also reduces unnecessary treatment costs and toxicity exposure. Mor Research is actively seeking partners for validation studies, regulatory advancement, and commercial rollout—transforming routine imaging into a powerful instrument for personalized cancer care.